ClinicalTrials.gg
CompletedNCT01969708SCORE2Updated Jun 22, 2021Results posted

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

A Phase 3 interventional study of aflibercept and bevacizumab in Central Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 72 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by The Emmes Company, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.

Enrollment
Largest of 21
362 · median 56
Started
2014
with 2 others
Phase 3
4 of 21
none open now
Registered
7th of 21
by date

Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one has the largest enrollment, is one of 3 that started in 2014, is one of 4 in phase 3, and was the 7th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing aflibercept in Retinal Vein Occlusion as a file.
02

Study summary

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

Read the detailed description

The primary objective of SCORE2 is to test for non-inferiority based on mean change from baseline in visual acuity letter score at Month 6 for eyes randomized to intravitreal bevacizumab every 4 weeks compared with eyes randomized to intravitreal aflibercept every 4 weeks using a non-inferiority margin of 5 letters.

Secondary objectives of SCORE2 are to:

  • compare the bevacizumab and the aflibercept groups with regards to central retinal thickness, as measured with spectral domain optical coherence tomography (SD-OCT), at Month 6 and change between baseline and Month 6;
  • assess Month 12 visual acuity and SD-OCT outcomes associated with different dosing strategies after Month 6 in participants who respond well to treatment;
  • assess Month 12 visual acuity and SD-OCT outcomes associated with alternative treatment strategies after Month 6 in participants who respond poorly to treatment;
  • compare area of retinal ischemia and rates of neovascular complications of CRVO in the bevacizumab vs. aflibercept groups;
  • add to our knowledge of the safety profile of these anti-vascular endothelial growth factor (VEGF) medications in the setting of eyes with macular edema secondary to CRVO;
  • conduct a cost effectiveness analysis comparing intravitreal bevacizumab to intravitreal aflibercept to assess the economic implications from a payor perspective using decision analytic methods.

Other exploratory aims of SCORE2 are to:

  • investigate the correlation of features identified through SD-OCT segmentation analysis, such as the inner segment-outer segment (IS-OS) junction (also known as the ellipsoid zone), with such characteristics as visual acuity and central retinal thickness;
  • investigate the correlation of area of peripheral retinal nonperfusion from widefield fluorescein angiography with visual acuity and central retinal thickness, and the prognostic value of baseline peripheral and central retina perfusion status in predicting disease course and treatment responsiveness;
  • investigate the correlation of features on adaptive optics imaging with such characteristics as visual acuity and central retinal thickness.
03

Conditions studied

  • Central Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have center-involved macular edema secondary to CRVO. Eyes may be enrolled as early as the time of diagnosis of the macular edema. The definition of CRVO used in SCORE will also be used for the purposes of SCORE2: a CRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in all 4 quadrants.
  • Due to the similarities of a hemiretinal vein occlusion (HRVO) to CRVO,HRVO will be classified as CRVO for the purposes of this clinical trial. Eyes classified as having a HRVO will be limited to no more than 25% of the planned sample size. A HRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g. telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in 5 or more clock hours but less than all 4 quadrants. Typically, a HRVO is a retinal vein occlusion that involves 2 altitudinal quadrants.
  • E-Early Treatment Diabetic Retinopathy Study (ETDRS)visual acuity score of greater than or equal to 19 letters (approximately 20/400) and less than or equal to 73 letters (approximately 20/40) by the ETDRS visual acuity protocol. The investigator must believe that a study eye with visual acuity between 19 and 33 letters is perfused.
  • Retinal thickness on SD-OCT measurement, defined as central subfield thickness of 300 µm or greater. If the SD-OCT measurement is taken from a Heidelberg Spectralis Machine, the central subfield thickness should be 320 µm or greater.
  • Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs.

Exclusion criteria

Exclusion Criteria:

  • A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers indicating difficulty in long term follow-up, likelihood of survival of less than 12 months).
  • Participation in an trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at time of study entry.
  • History of allergy to any anti-VEGF agent, , or component of the delivery vehicle.
  • The participant will be moving out of the area of the clinical site to an area not covered by another clinical site during the 12 months of the study.
  • Positive urine pregnancy test: all women of (those who are pre-menopausal and not surgically sterilized) may participate only if they have a negative urine pregnancy test, and if they do not intend to become pregnant during the timeframe of the study. Women who are sexually active with a male partner must agree to use at least one of the following methods: hormonal therapy such as oral, implantable or injectable chemical contraceptives; mechanical therapy such as spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner.
  • Women who are breast-feeding.
  • Examination evidence of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT thought to be contributing to macular edema.
  • An eye that, in the investigator's opinion, would not benefit from resolution of macular edema such as eyes with foveal atrophy, dense pigmentary changes or dense subfoveal hard exudates.
  • Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, iris neovascularization, Irvine-Gass Syndrome, prior macula-off rhegmatogenous retinal detachment).
  • Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract).
  • History of laser photocoagulation for macular edema within 3 months prior to randomization.
  • History of intravitreal corticosteroid within 4 months of randomization.
  • Intravitreal anti-VEGF injection within 2 months of randomization. Note: Enrollment will be limited to no more than 25% of the planned sample size with any history of anti-VEGF treatment. Once this number of eyes has been enrolled, any history of anti-VEGF treatment will be an exclusion criterion. For enrollment of study eyes with prior intravitreal anti-VEGF agents, in the opinion of the investigator, the treatment response to prior anti-VEGF treatment must be either incomplete or the study eye had developed recurrent CRVO-associated macular edema, such that the study eye would benefit from additional anti-VEGF treatment.
  • History of peribulbar or retrobulbar corticosteroid use for any reason within 2 months prior to randomization.
  • History of panretinal scatter photocoagulation (PRP) or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 3 months following randomization.
  • History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within 4 months prior to randomization or anticipated within the next 6 months following randomization.
  • History of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization.
  • Aphakia.
  • Presence of an anterior chamber intraocular lens
  • Examination evidence of external ocular infection, including conjunctivitis, chalazion or significant blepharitis.
  • History of macular detachment.
  • Examination evidence of any diabetic retinopathy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
362 participants (actual)

Study arms

  • Active comparator
    aflibercept

    2.0 mg aflibercept every 4 weeks

    Drug: aflibercept

  • Active comparator
    bevacizumab

    1.25 mg bevacizumab every 4 weeks

    Drug: bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6

    The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent.

    Time frame: Month 0 to 6

Secondary outcomes

  1. Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6

    The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6

    Time frame: Month 0 to 6

  2. Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6

    The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6

    Time frame: Month 0 to 6

  3. Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness

    The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography

    Time frame: Month 0 to 6

  4. Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6

    The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness

    Time frame: Month 0 to 6

  5. Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces

    The measure is the number of study eyes with central subfield thickness \<300 μm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6

    Time frame: Month 0 to 6

07

Results

Posted Aug 21, 2018

Participant flow

The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab.

Participant flow — Overall Study
MilestoneAfliberceptBevacizumab
Started180182
Completed175173
Not completed59

Outcome measures

PrimaryMean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6

The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent.

Time frame:
Month 0 to 6
Reported as:
Mean · letters read
Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6
letters readAfliberceptBevacizumab
Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 618.9 (16.62 to 21.15)18.6 (16.16 to 21.09)
SecondaryNumber of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6

The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6

Time frame:
Month 0 to 6
Reported as:
Number · study eyes
Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6
study eyesAfliberceptBevacizumab
Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6114106
SecondaryNumber of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6

The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6

Time frame:
Month 0 to 6
Reported as:
Number · study eyes
Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6
study eyesAfliberceptBevacizumab
Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 610199
SecondaryMean Spectral-domain Optical Coherence Tomography Central Subfield Thickness

The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography

Time frame:
Month 0 to 6
Reported as:
Mean · um
Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness
umAfliberceptBevacizumab
Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness231.3 (220.8 to 241.8)287.9 (269.4 to 306.4)
SecondaryMean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6

The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness

Time frame:
Month 0 to 6
Reported as:
Mean · um
Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6
umAfliberceptBevacizumab
Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6-425 (-461 to -389)-387 (-426 to -348)
SecondaryNumber of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces

The measure is the number of study eyes with central subfield thickness \<300 μm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6

Time frame:
Month 0 to 6
Reported as:
Number · study eyes
Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces
study eyesAfliberceptBevacizumab
Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces9249

Adverse events

Collected over Month 0 to 6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept1/180 (0.6%)14/180 (7.8%)82/180 (45.6%)
Bevacizumab1/182 (0.5%)14/182 (7.7%)98/182 (53.8%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventAfliberceptBevacizumab
PneumoniaInfections and infestations0/1802/182
Acute kidney injuryRenal and urinary disorders1/1800/182
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/1800/182
Ankle fractureInjury, poisoning and procedural complications1/1800/182
ArthritisMusculoskeletal and connective tissue disorders1/1800/182
BronchitisInfections and infestations1/1800/182
Cardiac failure congestiveCardiac disorders1/1800/182
Cerebrovascular accidentNervous system disorders1/1800/182
Diabetic foot infectionInfections and infestations1/1800/182
Escherichia infectionInfections and infestations1/1800/182
Most frequent other events
Showing 10 of 171
Most frequent other events
EventAfliberceptBevacizumab
Conjunctival haemorrhageEye disorders4/18014/182
Vitreous floatersEye disorders6/1808/182
Visual acuity reducedEye disorders3/1807/182
Eye painEye disorders6/1803/182
Vitreous detachmentEye disorders6/1803/182
HeadacheNervous system disorders2/1806/182
NasopharyngitisInfections and infestations3/1806/182
Urinary tract infectionInfections and infestations3/1806/182
FallInjury, poisoning and procedural complications2/1805/182
HypertensionVascular disorders3/1805/182

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AfliberceptBevacizumabTotal
<=18 years000
Between 18 and 65 years6767134
>=65 years113115228
Sex: Female, Male
Sex: Female, Male(Participants)AfliberceptBevacizumabTotal
Female8275157
Male98107205
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AfliberceptBevacizumabTotal
Hispanic or Latino162238
Not Hispanic or Latino164160324
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AfliberceptBevacizumabTotal
American Indian or Alaska Native8210
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American282654
White132146278
More than one race000
Unknown or Not Reported8614
Region of Enrollment
Region of Enrollment(participants)AfliberceptBevacizumabTotal
United States180182362
Visual Acuity Letter Score (VALS) of Study Eye
Visual Acuity Letter Score (VALS) of Study Eye(letters read)AfliberceptBevacizumabTotal
Mean50.3 ± 15.250.4 ± 15.350.3 ± 15.2
Time between diagnosis of macular edema and randomization
Time between diagnosis of macular edema and randomization(months)AfliberceptBevacizumabTotal
Mean8 ± 175 ± 107 ± 14
Spectral Domain-Optical Coherence Tomography (SD-OCT) central subfield thickness
Spectral Domain-Optical Coherence Tomography (SD-OCT) central subfield thickness(um)AfliberceptBevacizumabTotal
Mean652.4 ± 214.6678.2 ± 233.3665.5 ± 224.4

10 further baseline measures are reported on the registry.

08

Study locations

72 sites
  • Retinal Consultants of AZ
    Phoenix, Arizona 85014, United States
  • Retina Centers, P.C.
    Tucson, Arizona 85704, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • East Bay Retina Consultants, Inc.
    Oakland, California 94609, United States
  • Southern California Desert Retina Consultants
    Palm Desert, California 92211, United States
  • University of California Davis, Medical Center
    Sacramento, California 95817, United States
  • Retinal Consultants Medical Group, Inc.
    Sacramento, California 95819, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • New England Retina Associates
    New London, Connecticut 06320, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • University of Florida, Dept of Ophthalmology
    Jacksonville, Florida 32209, United States
  • Florida Retina Consultants
    Lakeland, Florida 33805, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Florida Retina Consultants
    Winter Haven, Florida 33880, United States
  • Emory University Eye Center
    Atlanta, Georgia 30322, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina, P.C.
    Marietta, Georgia 30060, United States
  • Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology
    Chicago, Illinois 60612, United States
  • Thomas A. Ciulla, MD, PC
    Indianapolis, Indiana 46290, United States
  • Sabates Eye Centers
    Leawood, Kansas 66211, United States
  • Retina Associates, PA
    Shawnee Mission, Kansas 66204, United States
  • Retina Associates of Kentucky
    Lexington, Kentucky 40509, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Elman Retina Group, PA
    Baltimore, Maryland 21237, United States
  • The Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Elman Retina Group, P.A.
    Glen Burnie, Maryland 21061, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Elman Retina Group, P.A.
    Pikesville, Maryland 21208, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • TLC Eyecare & Laser Centers
    Jackson, Michigan 49202, United States
  • VitreoRetinal Surgery
    Minneapolis, Minnesota 55435, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • The Retina Institute
    Saint Louis, Missouri 63128, United States
  • UNMC Truhlsen Eye Institute
    Omaha, Nebraska 68198, United States
  • Retina Consultants of Nevada
    Las Vegas, Nevada 89144, United States
  • Delaware Valley Retina Associates
    Lawrenceville, New Jersey 08648, United States
  • NJ Retina
    New Brunswick, New Jersey 08901, United States
  • New York Eye and Ear Infirmary
    New York, New York 10003, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • University of Rochester Flaum Eye Institute
    Rochester, New York 14642, United States
  • Retina Vitreous Surgeon of CNY, PC
    Syracuse, New York 13224, United States
  • Charlotte Eye Ear Nose & Throat Associates, P.A.
    Charlotte, North Carolina 28210, United States
  • Charlotte Eye Ear Nose & Throat Associates, P.A.
    Statesville, North Carolina 28677, United States
  • Retina Associates of Cleveland, Inc.
    Cleveland, Ohio 44122, United States
  • The Ohio State University
    Columbus, Ohio 43212, United States
  • Dean McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Retina Northwest, PC
    Portland, Oregon 97210, United States
  • Casey Eye Institute / OHSU
    Portland, Oregon 97239, United States
  • Retina Vitreous Consultants
    Monroeville, Pennsylvania 15146, United States
  • Scheie Eye Institute
    Philadelphia, Pennsylvania 19104, United States
  • Carolinas Centers for Sight, PC
    Florence, South Carolina 29501, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Southeastern Retina Associates, PC
    Knoxville, Tennessee 37909, United States
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
  • Vanderbilt Eye Institute
    Nashville, Tennessee 37232-8808, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Arlington, Texas 76012, United States
  • The Retina Research Center
    Austin, Texas 78705, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Charlotte Eye Ear Nose & Throat Associates, P.A.
    Houston, Texas 77025, United States
  • Retina & Vitreous of Texas
    Houston, Texas 77025, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retinal Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • The Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M; SCORE2 Investigator Group. SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion. Am J Ophthalmol. 2016 Oct;170:25-31. doi: 10.1016/j.ajo.2016.07.011. Epub 2016 Jul 19. PubMed 27450625 ↗
  • Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group. SCORE2 Report 2: Study Design and Baseline Characteristics. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub 2016 Nov 15. PubMed 27863843 ↗
  • Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M; SCORE2 Investigator Group. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141. PubMed 28492860 ↗
  • Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE2 Investigator Group. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2017 Dec;184:147-156. doi: 10.1016/j.ajo.2017.10.008. Epub 2017 Oct 23. PubMed 29074161 ↗
  • Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM; SCORE2 Investigator Group. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Apr 1;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843. PubMed 29476687 ↗
  • Peterson JS, Rockwell K Jr, Scott IU, Ip MS, VanVeldhuisen PC, Blodi BA; SCORE2 Investigator Group. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS. Retina. 2019 Sep;39(9):1802-1809. doi: 10.1097/IAE.0000000000002212. PubMed 29746405 ↗
  • Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. JAMA Ophthalmol. 2019 Mar 1;137(3):281-287. doi: 10.1001/jamaophthalmol.2018.6111. PubMed 30589922 ↗
  • Etheridge T, Dobson ETA, Wiedenmann M, Papudesu C, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study. PLoS One. 2020 Apr 30;15(4):e0232494. doi: 10.1371/journal.pone.0232494. eCollection 2020. PubMed 32353052 ↗
  • Hendrick A, VanVeldhuisen PC, Scott IU, King J, Blodi BA, Ip MS, Khurana RN, Oden NL; SCORE2 Investigator Group. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials. Am J Ophthalmol. 2021 Feb;222:185-193. doi: 10.1016/j.ajo.2020.08.030. Epub 2020 Aug 20. PubMed 32828880 ↗
  • Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14. Transl Vis Sci Technol. 2021 Mar 1;10(3):31. doi: 10.1167/tvst.10.3.31. PubMed 34003964 ↗
  • Etheridge T, Blodi B, Oden N, Van Veldhuisen P, Scott IU, Ip MS, Mititelu M, Domalpally A. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15. Ophthalmol Retina. 2021 Oct;5(10):991-998. doi: 10.1016/j.oret.2020.12.016. Epub 2020 Dec 26. PubMed 33373715 ↗
  • Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568. PubMed 28492910 ↗
  • Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA; SCORE2 Investigator Group. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2022 Aug;240:330-341. doi: 10.1016/j.ajo.2022.04.001. Epub 2022 Apr 21. PubMed 35461831 ↗
  • Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. PubMed 34709363 ↗
  • Khurana RN, Oden NL, VanVeldhuisen PC, Scott IU, Blodi BA, Ip MS; SCORE2 Investigator Group. Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial. Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):1839-1851. doi: 10.1007/s00417-020-05018-7. Epub 2021 Jan 7. PubMed 33415354 ↗
  • Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Chan CK; SCORE2 Investigator Group. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2019 Dec 1;137(12):1389-1398. doi: 10.1001/jamaophthalmol.2019.3947. PubMed 31600368 ↗
  • Scott IU, VanVeldhuisen PC, Barton F, Oden NL, Ip MS, Blodi BA, Worrall M, Fish GE; Study of Comparative Treatments for Retinal Vein Occlusion 2 Investigator Group. Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2019 Aug 1;137(8):932-938. doi: 10.1001/jamaophthalmol.2019.1519. PubMed 31169862 ↗

Individual participant data

Plan to share: Yes — SCORE2 will follow specific plans for sharing of research data. After analysis, the final data set can be provided after appropriate procedures are implemented to preserve the anonymity of the records, specifically where protected health information (PHI) is required. Upon request, anonymized data will be shared under confidentiality agreements with researchers interested in the project.

Time frame: The time frame will be determined

Access criteria: Confidentiality agreements will be required before anonymized data will be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Nov 2016, 26 months.

Results were first posted in Aug 2018, 1 year 9 months after primary completion.

Of 18 phase 3 interventional studies under Retinal Vein Occlusion, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 25, 2013
StartActual
Sep 2014
Primary completionActual
Nov 2016
CompletionActual
Mar 2021
Results first posted
Aug 21, 2018
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01969708
Lead sponsor
The Emmes Company, LLC
Responsible party
Sponsor
First posted
Oct 25, 2013
Start date
Sep 2014
Primary completion
Nov 2016
Completion
Mar 2021
Results posted
Aug 21, 2018
Last update
Jun 22, 2021

Study contacts

Ingrid U Scott, M.D., M.P.H.
study chair · Penn State College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflibercept · Bevacizumab

Start the discussion